Endogenous Carbon Monoxide; We Don’t Know

Endogenous Carbon Monoxide (CO) is a gas involved in cell signalling events that are necessary for the regulation of biological systems. However, it leads to impaired efficiency of oxygen storage and transport by haemoglobin (Hb) through CO protein binding to haem. People breathing air without an environmental CO source will still have measurable levels of circulating COHb due to both protein catabolism and endogenous CO production. Endogenous CO is produced from the oxidative degradation of both proteins by the stress response enzyme haem oxygenase (HO). HO acts as a defence mechanism against oxidative stress and is induced by reactive oxygen species. CO production may be affected by various physiological factors, including disease [1]. In normal degradation of Hb, the porphyrin ring of the hem is broken with HO at the α-methine bridge. HO coexists with NADPH-flavoprotein reductase and biliverdin reductase on the endoplasmic reticulum, where it catabolizes haem, biliverdin, iron and CO in an O2 and NADPH-dependent manner. Biliverdin is then separated by biliverdin reductase, bilirubin, a potent endogenous antioxidant [2]. Increased levels of both after erythrocyte destruction, increased endogenous CO production and increased COHb levels have been shown [3, 4]. When haemolysis and abnormal metabolism increase, the CO production rate in our body can increase significantly [4]. Both are the main site of catabolism and thus the main organ of CO production in the liver. Following the liver, spleen, brain and erythropoietic systems are organs and systems in which CO production occurs [5]. CO formation rates may be due to high levels of HO activity in these tissues [3, 4, 6]. Although CO was previously known only as a toxic gas with high binding properties to haemoglobin, it has now been shown to play an important role in many physiological and pathophysiological processes in the cardiovascular, immune and neurological systems [7]. The physiological effect of CO occurs as nitric oxide increases the production of cyclic guanylate cyclase (cGMP) as well as increases soluble cGMP [8]. CO, which has antiapoptotic and anti-inflammatory potential, has vasodilatation properties on the cardiovascular system [9]. Although the cytoprotective roles of CO, in vitro studies using CO-releasing molecules, and in vivo studies using high exogenous CO exposure have been investigated, the behaviour of CO under pathophysiological conditions is still unknown [10]. While CO levels measured by carboxyhaemoglobin (COHb) have been shown to have high concentrations in smokers, endogenous CO concentration levels of those with various pathophysiological conditions are uncertain [11]. There are several research articles related to endogenous COHb and diseases. One of them is the work of Kobayashi et al. Kobayashi et al. Investigated the relationship between endogenous COHb and ACS and divided them into four groups as non-smoker ACS and non-smoker ACS in 235 patients. As expected, COHb levels were higher in smokers. In this study, it was concluded that endogenous CO may be useful for evaluating the risk of cardiovascular stress [12]. One of the diseases investigated in relation to endogenous COHb and diseases is pulmonary embolism. Kakavas et al. Investigated COHb levels and prognosis in patients with pulmonary embolism. This study was retrospectively performed on 156 patients. In univariate logistic regression analysis, COHb levels were associated with mortality and in multivariate analysis only COHb was
found to be an independent predictor of in-hospital mortality [13] as a result, endogenous COHb can still be studied in many diseases.

REFERENCES